Biocon Generics returns to EBITDA profit in first-half FY27

Biocon Generics returned to EBITDA profit in H1 FY27, reporting Rs 120 crore against a Rs 28 crore loss in H1 FY26, as revenue rose 15% to Rs 1,536 crore and the EBITDA margin moved to 8% from negative 2%. Management attributed the improvement to capacity utilisation, operating leverage and productivity initiatives.

What drove Biocon Generics’ H1 FY27 EBITDA turnaround?

Biocon Generics’ H1 FY27 turnaround was driven by higher revenue, improved capacity utilisation, operating leverage and productivity initiatives, according to management. Segment revenue increased by Rs 204 crore, or 15%, year on year to Rs 1,536 crore from Rs 1,332 crore. EBITDA changed by Rs 148 crore, from a loss of Rs 28 crore to a profit of Rs 120 crore, while the reported margin rose from negative 2% to 8%.

The shift means the segment delivered positive EBITDA in both quarters of the first half rather than only narrowing a loss. Q1 FY27 EBITDA was Rs 56 crore and Q2 FY27 EBITDA was Rs 64 crore. The H1 FY27 margin was 10 percentage points above the H1 FY26 margin shown in the presentation. Biocon Generics also reported that EBITDA margin expanded by over 700 basis points, or bps, year on year in Q2 FY27.

The H1 FY26 comparative figures exclude a cross-charge for common utilities that was earlier included within Generics and is now included under unallocable expenditure or income. That footnote applies to the comparative quarterly and first-half figures on the slide. It is therefore relevant to how Biocon Generics presents the year-on-year revenue, research and development, or R&D, and EBITDA comparison.

How did Biocon Generics perform in Q2 FY27?

Biocon Generics reported Rs 774 crore of revenue and Rs 64 crore of EBITDA in Q2 FY27, with revenue up 10% year on year and EBITDA up 815%. The quarterly EBITDA margin reached 8%, compared with 1% in Q2 FY26, while the presentation says the margin expanded by over 700 bps over the prior-year quarter.

The Q2 result also improved sequentially from Q1 FY27. Revenue rose 2% from Rs 760 crore in Q1 FY27 to Rs 774 crore in Q2 FY27, and EBITDA rose 15% from Rs 56 crore to Rs 64 crore. The margin increased by one percentage point from 7% in Q1 FY27 to 8% in Q2 FY27, showing that the segment maintained profitability while generating modest quarter-on-quarter revenue growth.

On a year-on-year basis, Q2 EBITDA increased by Rs 57 crore from Rs 7 crore, while revenue rose by Rs 73 crore from Rs 701 crore. R&D declined by Rs 36 crore to Rs 35 crore. The presentation provides the 8% versus 1% margin comparison, but does not allocate the EBITDA change among revenue growth, R&D movement and productivity initiatives.

The two quarters together explain the Rs 120 crore H1 EBITDA result. Q2 EBITDA of Rs 64 crore was Rs 8 crore higher than the Rs 56 crore recorded in Q1 FY27, while quarterly revenue was Rs 14 crore higher. Q2 FY27 therefore supplied more than half of first-half EBITDA and retained the same 8% margin reported for H1 FY27.

How did R&D spending change at Biocon Generics?

Biocon Generics reduced reported R&D expense to Rs 82 crore in H1 FY27 from Rs 141 crore in H1 FY26, a decline of 42%. R&D represented 5% of H1 revenue, compared with 11% a year earlier. The reduction occurred alongside a Rs 204 crore increase in segment revenue and the move from a Rs 28 crore EBITDA loss to Rs 120 crore of EBITDA profit.

In Q2 FY27, R&D expense was Rs 35 crore, down 51% year on year from Rs 71 crore and down 26% sequentially from Rs 47 crore in Q1 FY27. R&D represented 5% of Q2 revenue, compared with 10% in Q2 FY26 and 6% in Q1 FY27. The presentation does not give a separate explanation for the R&D reduction, beyond identifying capacity utilisation, operating leverage and productivity initiatives as drivers of the overall profitability improvement.

Management also identified product areas underpinning the next phase of growth: peptides, fermentation and complex formulations. Liraglutide was described as gaining traction across markets and strengthening Biocon Generics’ complex injectables portfolio. The presentation does not disclose revenue, market share, launch dates or profitability for liraglutide, peptides, fermentation or complex formulations, so their individual contribution to the Rs 1,536 crore H1 revenue total is not specified.

What could support further improvement at Biocon Generics?

Management said continued execution and operating leverage are expected to support further improvement in Biocon Generics’ profitability. The stated operational mechanisms are the same ones associated with the Q2 FY27 margin improvement: better capacity utilisation, productivity initiatives and operating leverage. The segment’s Q2 FY27 8% EBITDA margin was higher than the 7% margin in Q1 FY27 and the 1% margin in Q2 FY26.

The disclosed growth platform includes liraglutide, peptides, fermentation and complex formulations. Management said liraglutide is gaining traction across markets, while peptides, fermentation and complex formulations underpin the next phase of growth. These are forward-looking management statements rather than quantified forecasts: the presentation provides no revenue target, EBITDA target, launch timetable or capacity figure for Biocon Generics.

The immediate operating benchmark will be whether revenue growth and the 8% EBITDA margin can be sustained beyond H1 FY27. Revenue grew 15% in H1 FY27 but only 2% sequentially in Q2 FY27, while EBITDA rose 15% sequentially to Rs 64 crore. The slide does not quantify capacity utilisation, plant productivity or operating-cost savings, and it does not state whether any part of the improvement is non-recurring.

Conclusion

Biocon Generics’ first-half result marks a reported move from a Rs 28 crore EBITDA loss in H1 FY26 to Rs 120 crore of EBITDA in H1 FY27. Revenue increased 15% to Rs 1,536 crore, the EBITDA margin reached 8%, and R&D expense fell to 5% of revenue from 11%. Q2 FY27 extended the pattern, with EBITDA of Rs 64 crore and an 8% margin.

The next point to watch is management’s execution on continued operating leverage, capacity utilisation and productivity initiatives, which it says can support additional profitability improvement. Management has also pointed to liraglutide traction and to peptides, fermentation and complex formulations as the next growth phase, but the presentation gives no dated targets or quantified outlook for these products and platforms.